Correlating tumor-infiltrating lymphocytes and lung cancer stem cells: a cross-sectional study.
Tumor-infiltrating lymphocytes (TILS)
cancer stem cells (CSCs)
cancer stem-like cells
immunotherapy
non-small cell lung cancer (NSCLC)
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
entrez:
14
1
2020
pubmed:
14
1
2020
medline:
14
1
2020
Statut:
ppublish
Résumé
Lung cancer stem cells (LCSCs) are endowed with high aldehyde dehydrogenase (ALDH) expression and play roles in tumor proliferation, metastasis, and drug resistance. Their elusive nature may allow them to escape the immune response by tumor-infiltrating lymphocytes (TILs), which can positively affect the outcome in non-small cell lung cancer (NSCLC) patients. Despite independent investigations on both LCSCs and TILs, the relationship between the two has been very marginally considered. We analyzed whether these two cell types may be related as a prerequisite for novel diagnostic and therapeutic approaches. In this cross-sectional study, NSCLC human surgical specimens from 12 patients were tested by ALDEFLUOR assay to identify ALDH Statistically positive correlations were found between ALDH+ and CD8+, and between ALDH+ and CD3+ cells populations; no correlation was found between ALDH+ and CD4+ cells. The expression of CD3+ and CD8+ by cells accounted for 40.1% and 58.7%, respectively, of the variability of ALDH+ cell expression by an R-squared index, which highlights the strong correlation between TILs and LCSCs. Immunohistochemistry revealed 6-25% positive cells. We report a correlation between cytotoxic TILs and LCSCs, which may contribute to the future development of targeted therapies focusing on the different roles of lymphocytes against lung cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer stem cells (LCSCs) are endowed with high aldehyde dehydrogenase (ALDH) expression and play roles in tumor proliferation, metastasis, and drug resistance. Their elusive nature may allow them to escape the immune response by tumor-infiltrating lymphocytes (TILs), which can positively affect the outcome in non-small cell lung cancer (NSCLC) patients. Despite independent investigations on both LCSCs and TILs, the relationship between the two has been very marginally considered. We analyzed whether these two cell types may be related as a prerequisite for novel diagnostic and therapeutic approaches.
METHODS
METHODS
In this cross-sectional study, NSCLC human surgical specimens from 12 patients were tested by ALDEFLUOR assay to identify ALDH
RESULTS
RESULTS
Statistically positive correlations were found between ALDH+ and CD8+, and between ALDH+ and CD3+ cells populations; no correlation was found between ALDH+ and CD4+ cells. The expression of CD3+ and CD8+ by cells accounted for 40.1% and 58.7%, respectively, of the variability of ALDH+ cell expression by an R-squared index, which highlights the strong correlation between TILs and LCSCs. Immunohistochemistry revealed 6-25% positive cells.
CONCLUSIONS
CONCLUSIONS
We report a correlation between cytotoxic TILs and LCSCs, which may contribute to the future development of targeted therapies focusing on the different roles of lymphocytes against lung cancer.
Identifiants
pubmed: 31930020
doi: 10.21037/atm.2019.11.27
pii: atm-07-22-619
pmc: PMC6944548
doi:
Types de publication
Journal Article
Langues
eng
Pagination
619Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
2019 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Sci Rep. 2015 Oct 08;5:14896
pubmed: 26447332
J Cancer. 2017 Sep 15;8(16):3190-3197
pubmed: 29158791
Blood. 2009 Feb 19;113(8):1670-80
pubmed: 18971422
Eur J Cancer. 2019 Jan;106:144-159
pubmed: 30528799
Oncotarget. 2016 Feb 9;7(6):7227-40
pubmed: 26811495
Eur J Cardiothorac Surg. 2015 Aug;48(2):180-93
pubmed: 25971435
Stem Cells. 2015 Jul;33(7):2085-92
pubmed: 25873269
BMC Cancer. 2014 Apr 30;14:304
pubmed: 24884875
Cytotherapy. 2007;9(3):259-74
pubmed: 17464758
Mod Pathol. 2011 May;24(5):671-82
pubmed: 21240258
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
Stem Cells Int. 2016;2016:5603135
pubmed: 26880969
Biomedicine (Taipei). 2017 Dec;7(4):23
pubmed: 29130448
Chin Med J (Engl). 2015 Jan 5;128(1):105-10
pubmed: 25563322
J Thorac Oncol. 2016 Sep;11(9):1433-46
pubmed: 27448762
Biochim Biophys Acta. 2015 Dec;1856(2):189-210
pubmed: 26297204
Cureus. 2018 Sep 4;10(9):e3254
pubmed: 30416904
Nat Prod Res. 2007 Jan;21(1):13-7
pubmed: 17365682
Front Immunol. 2019 Feb 01;9:3101
pubmed: 30774636
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Cancer Gene Ther. 2017 Feb;24(2):57-63
pubmed: 28084319
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Transl Lung Cancer Res. 2015 Dec;4(6):689-703
pubmed: 26798578
Cancer Res. 2010 Dec 1;70(23):9937-48
pubmed: 21118965
Cancer Immunol Immunother. 2009 Oct;58(10):1535-44
pubmed: 19562338
Cancer Res. 1992 Apr 1;52(7):1770-4
pubmed: 1551107
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Int J Mol Sci. 2019 Jun 08;20(11):null
pubmed: 31181772
Oncol Lett. 2018 Jun;15(6):8187-8194
pubmed: 29805553
Cell Death Differ. 2014 Jan;21(1):5-14
pubmed: 23579243
Intractable Rare Dis Res. 2017 Nov;6(4):234-241
pubmed: 29259850
J Oral Maxillofac Pathol. 2017 Sep-Dec;21(3):463
pubmed: 29391738
Onco Targets Ther. 2014 Jun 23;7:1129-34
pubmed: 25018639
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711